News

Therapeutic RANK inhibition reduces breast cancer recurrence

Researchers at the Institute of Biomedical Research of Bellvitge (IDIBELL), led by Dr. Eva Gonzalez-Suarez, have shown that pharmacological and genetic inhibition of signaling pathway RANK / RANKL leads to a significant reduction in recurrences and metastases in breast cancer in a mouse animal model. Their findings, published in Cancer Research, suggest that RANK inhibitors […]

Leer más about Therapeutic RANK inhibition reduces breast cancer recurrence

Dr. Conxi Lázaro is awarded the Theodor Schwann Prize for his research in the field of neurofibromatosis

Dr. Conxi Lázaro, director of the Molecular Diagnostic Unit of the ICO-IDIBELL Hereditary Cancer Program, has received the prestigious Theodor Schwann prize awarded by the European Association of Neurofibromatosis. This award is named after the German physiologist who identified the cells responsible for tumors present in patients with neurofibromatosis type 1, the Schwann cells. Dr. […]

Leer más about Dr. Conxi Lázaro is awarded the Theodor Schwann Prize for his research in the field of neurofibromatosis

Catalonia’s Parliament awards its medal of honor to IDIBELL’s researcher Manel Esteller

Catalonia’s parliament has given today, as part of the celebration of the National Day of Catalonia, the medal of honor in the category of gold to Dr. Manel Esteller, “for his career as a Catalan physician and researcher of international reference”. During the ceremony, the president Carmen Forcadell, and the president of the Generalitat, Carles […]

Leer más about Catalonia’s Parliament awards its medal of honor to IDIBELL’s researcher Manel Esteller

Tumor microenvironment acts as a mechanism of resistance to chemotherapy in colorectal cancer

A new study highlights the importance of the tumor environment as a source of resistance to treatment in colorectal cancer, the fourth most common cancer and the leading cause of cancer death worldwide.

Leer más about Tumor microenvironment acts as a mechanism of resistance to chemotherapy in colorectal cancer

The first epigenetic test to identify tumors of unknown primary

The EPICUP® test is a new tool that helps identify up to 87% of cases of cancer of unknown origin (CUP) Article Esteller M The Lancet Oncology

Leer más about The first epigenetic test to identify tumors of unknown primary

Not all tumor cells are equal

Scientists find that colorectal tumors present epigenetic heterogeneity relates to the clinical course of the disease. Article citation Esteller M Gastroenterology

Leer más about Not all tumor cells are equal

Alvaro Aytes receives one of 60 grants from the BBVA Foundation for researchers and creators

With this initiative, the BBVA Foundation promotes individual effort for the collective benefit of professionals in an intermediate stage of his career and who have demonstrated high productivity and innovativeness the BBVA Foundation has awarded one of the Grants for Researchers and Cultural Creators

Leer más about Alvaro Aytes receives one of 60 grants from the BBVA Foundation for researchers and creators

Manel Esteller, Joan Massagué and Josep Baselga are awarded the Catalunya International Prize

The oncologists Manel Esteller, Joan Massagué and Josep Baselga are the winners of the 28th Catalunya International Prize “for his revolutionary task, especially on oncology research, with what they significantly contributed to the advances of global medicine”. The awards, recently announced by the President of the Generalitat de Catalunya (Catalan Government), Carles Puigdemont, are given […]

Leer más about Manel Esteller, Joan Massagué and Josep Baselga are awarded the Catalunya International Prize
Scroll to Top